RT Journal
A1 Jay JS, Gostin LO
T1 EThical challenges of preexposure prophylaxis for hiv
JF JAMA
JO JAMA
YR 2012
FD September 5
VO 308
IS 9
SP 867
OP 868
DO 10.1001/2012.jama.10158
UL http://dx.doi.org/10.1001/2012.jama.10158
AB 
On July 16, 2012, emtricitabine/tenofovir (Truvada; Gilead Sciences) became the first drug approved by the US Food and Drug Administration (FDA) for preexposure prophylaxis (PrEP) of human immunodeficiency virus (HIV) for adults at high risk. Clinical trials have demonstrated that daily use of oral antiretroviral drugs can reduce the risk of HIV acquisition through sexual intercourse. With 50 000 new HIV infections per year in the United States1 and 2 million per year worldwide,2 PrEP could become a major component of “combination prevention” along with condoms, counseling, testing, and treatment.